Jasper Therapeutics Statistics
Share Statistics
Jasper Therapeutics has 15.00M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 15.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -1.28 and the forward PE ratio is null.
| PE Ratio | -1.28 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.05 |
| P/FCF Ratio | -1.57 |
| PEG Ratio | n/a |
Enterprise Valuation
Jasper Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 7.19, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.19 |
| Quick Ratio | 7.19 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.22 |
| Cash Flow / Debt | -53.57 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.82% and return on capital (ROIC) is -82.69%.
| Return on Equity (ROE) | -0.82% |
| Return on Assets (ROA) | -0.68% |
| Return on Capital (ROIC) | -82.69% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.43M |
| Employee Count | 45 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -1.63M |
| Effective Tax Rate | 0.02 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 2.2, so Jasper Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.2 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.18 |
| Relative Strength Index (RSI) | 54.89 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Jasper Therapeutics had revenue of $0 and earned -$64.47M in profits. Earnings per share was $-6.18.
| Revenue | 0 |
| Gross Profit | -1.11M |
| Operating Income | -68.86M |
| Net Income | -64.47M |
| EBITDA | -64.98M |
| EBIT | - |
| Earnings Per Share (EPS) | -6.18 |
Balance Sheet
The company has $86.89M in cash and $2.79M in debt, giving a net cash position of $84.10M.
| Cash & Cash Equivalents | 86.89M |
| Total Debt | 2.79M |
| Net Cash | 84.10M |
| Retained Earnings | -169.60M |
| Total Assets | 99.41M |
| Working Capital | 82.35M |
Cash Flow
In the last 12 months, operating cash flow was -$52.07M and capital expenditures -$267.00K, giving a free cash flow of -$52.33M.
| Operating Cash Flow | -52.07M |
| Capital Expenditures | -267.00K |
| Free Cash Flow | -52.33M |
| FCF Per Share | -5.01 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
JSPRW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for JSPRW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -4.18 |
| Piotroski F-Score | 0 |